John Shaughnessy
Overview
Explore the profile of John Shaughnessy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
899
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lazarevic V, Wahlin A, Hultdin M, Zhan F, Shaughnessy J
Leuk Lymphoma
. 2006 Oct;
47(9):1987-8.
PMID: 17065022
No abstract available.
12.
Hardin J, Waddell M, Page C, Zhan F, Barlogie B, Shaughnessy J, et al.
Stat Appl Genet Mol Biol
. 2006 May;
3:Article10.
PMID: 16646788
Motivation: Standard laboratory classification of the plasma cell dyscrasia monoclonal gammopathy of undetermined significance (MGUS) and the overt plasma cell neoplasm multiple myeloma (MM) is quite accurate, yet, for the...
13.
Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al.
N Engl J Med
. 2006 Mar;
354(10):1021-30.
PMID: 16525139
Background: High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further...
14.
Takebe N, Cheng X, Fandy T, Srivastava R, Wu S, Shankar S, et al.
Mol Cancer Ther
. 2006 Mar;
5(2):457-66.
PMID: 16505121
Multiple myeloma is an incurable disease for the majority of patients, therefore requiring new biological targeted therapies. In primary myeloma cells, IMP dehydrogenase (IMPDH) was shown to be consistently overexpressed....
15.
Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, et al.
Blood
. 2005 Dec;
107(7):2633-8.
PMID: 16322468
Patients with myeloma, treated on the thalidomide arm of total therapy 2 (TT2), had a higher complete response (CR) rate and improved event-free survival (EFS) but not overall survival (OS)....
16.
Shaughnessy J
Hematology
. 2005 Sep;
10 Suppl 1:117-26.
PMID: 16188652
The molecular basis for aggressive transformation of multiple myeloma (MM) and other cancers is not completely understood. Global gene expression profiling on highly purified malignant plasma cells from 351 newly...
17.
van Rhee F, Szmania S, Zhan F, Gupta S, Pomtree M, Lin P, et al.
Blood
. 2005 Jan;
105(10):3939-44.
PMID: 15671442
The presence of a metaphase cytogenetic abnormality (CA) is the key negative predictor of outcome in patients with multiple myeloma (MM). Gene expression profiling (GEP) of such patients showed increased...
18.
Takebe N, Cheng X, Wu S, Bauer K, Goloubeva O, Fenton R, et al.
Clin Cancer Res
. 2004 Dec;
10(24):8301-8.
PMID: 15623606
Purpose: Inosine monophosphate dehydrogenase (IMPDH) inhibitors have been used to induce leukemia blast cell differentiation but have not been tested in multiple myeloma for activity. Currently, available IMPDH inhibitor, mycophenolate...
19.
Kelly T, Miao H, Yang Y, Navarro E, Kussie P, Huang Y, et al.
Cancer Res
. 2003 Dec;
63(24):8749-56.
PMID: 14695190
Heparanase is an enzyme that cleaves heparan sulfate chains of proteoglycans, and its expression has been associated with increased growth, metastasis, and angiogenesis of some tumors. Because myeloma tumor cells...
20.
Barille-Nion S, Barlogie B, Bataille R, Bergsagel P, Epstein J, Fenton R, et al.
Hematology Am Soc Hematol Educ Program
. 2003 Nov;
:248-78.
PMID: 14633785
Even during this past year, further advances have been made in understanding the molecular genetics of the disease, the mechanisms involved in the generation of myeloma-associated bone disease and elucidation...